Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 3/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 8/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4165837 | 0.89 | TDP2 (0.45) | TDP2AOC3MCHR1MAPTATM | |
| SCHEMBL4166736 | 0.89 | TDP2 (0.42) | TDP2AOC3MCHR1MAPTATM | |
| SCHEMBL4169596 | 0.89 | TDP2 (0.45) | TDP2AOC3MCHR1MAPTATM | |
| SCHEMBL4167556 | 0.88 | TDP2 (0.42) | TDP2AOC3MCHR1MAPTATM | |
| SCHEMBL4161595 | 0.86 | TDP2 (0.42) | TDP2AOC3MCHR1MAPTATM | |
| SCHEMBL4158662 | 0.85 | TDP2 (0.42) | TDP2AOC3MCHR1MAPTATM | |
| SCHEMBL4169122 | 0.84 | TDP2 (0.41) | TDP2AOC3MCHR1MAPTATM | |
| SCHEMBL4165534 | 0.83 | MAPT (0.56) | MAPTGRM1 | |
| SCHEMBL4165708 | 0.76 | GRM1 (0.42) | AOC3MCHR1MAPTPTGS2GRM1 | |
| SCHEMBL4173644 | 0.76 | GRM1 (0.41) | MCHR1MAPTPTGS2GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1999132-B1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM LLC (BM) | 2012-07-18 | — | — | EP | claimed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | claimed |
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| EP-1999132-B1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM LLC (BM) | 2012-07-18 | — | — | EP | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| EP-1999132-A1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM, LLC (BM) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007120454-A1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM LLC (BM) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | CNR1, CNR2, ITPR2 | TDP2 3658/4885AOC3 3023/4885MCHR1 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.